Ayana Pharma Overview
Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma. Co-founded by one of Doxils co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.
Cumulative Funding Raised Over Time ($)
—
Latest News
growth-positive
Can zero gravity help cure cancer? Israelis sent a drug to space to find out
An Israeli cancer drug called Doxil has returned to Earth after being tested on the International Space Station (ISS) to determine if it is more effective in microgravity. The inventor of Doxil, Prof. Yehezkel Bernholtz, is analyzing the results to see if treating cancer patients in space-like conditions could have benefits. The drug was sent to the ISS in January and has now returned to Earth for further analysis. The potential of exomedicine, the study of medicine in zero gravity, is of interest to NASA and others. Doxil is considered well-suited for space studies due to its complex structure. The results of the analysis are expected to provide insights into the impact of microgravity on the drug and its effectiveness against cancer cells.
Partners
growth-positive
Huston, we're solving cancer problems...
Ayana Pharmas cancer treatment drug, Doxil, was launched to the International Space Station as part of SpaceXs mission. The drugs launch was made possible by Israeli start-up SpacePharmas smart laboratory. The purpose of the experiment is to test if Doxil would change in zero-gravity conditions and to understand its effectiveness in non-gravity conditions. Ayana Pharmas drug development was led by Prof. Yehezkel Bernholtz, and the companys main investors include the Education Fund for Teachers and Kindergarten Teachers in Israel, the Integra Holdings Fund, the Ilan Holdings Fund, and Dr. Shmuel Kabili.
Partners
Generic, cancer-killing Israeli drug approved for marketing by FDA
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 1 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.ayanapharma.com/ |
Locations
Ein Kerem Street 95744, Jerusalem, Israel
Photos & Videos
No files yet
Ayana Pharma Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug DeliveryTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersPatientsCore Technology
BiologicalsTags (7)
cancergeneric-drugsmedical-technologiesdrug-deliveryspace-techpharmaceuticalshospitalsGeographic Markets
United StatesAyana Pharma Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Mature
Funding stage
1
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
—
Private Equity Funding
Undisclosed Round
Undisclosed
Integra Holdings, Yechezkel Barenholz
Ayana Pharma Lifecycle
Cumulative Funding Raised Over Time
—
All Events
Undisclosed Round
Undisclosed
Integra Holdings, Yechezkel Barenholz
Ayana Pharma News
3 articles
growth-positive
Can zero gravity help cure cancer? Israelis sent a drug to space to find out
An Israeli cancer drug called Doxil has returned to Earth after being tested on the International Space Station (ISS) to determine if it is more effective in microgravity. The inventor of Doxil, Prof. Yehezkel Bernholtz, is analyzing the results to see if treating cancer patients in space-like conditions could have benefits. The drug was sent to the ISS in January and has now returned to Earth for further analysis. The potential of exomedicine, the study of medicine in zero gravity, is of interest to NASA and others. Doxil is considered well-suited for space studies due to its complex structure. The results of the analysis are expected to provide insights into the impact of microgravity on the drug and its effectiveness against cancer cells.
Partners
growth-positive
Huston, we're solving cancer problems...
Ayana Pharmas cancer treatment drug, Doxil, was launched to the International Space Station as part of SpaceXs mission. The drugs launch was made possible by Israeli start-up SpacePharmas smart laboratory. The purpose of the experiment is to test if Doxil would change in zero-gravity conditions and to understand its effectiveness in non-gravity conditions. Ayana Pharmas drug development was led by Prof. Yehezkel Bernholtz, and the companys main investors include the Education Fund for Teachers and Kindergarten Teachers in Israel, the Integra Holdings Fund, the Ilan Holdings Fund, and Dr. Shmuel Kabili.
Partners
Generic, cancer-killing Israeli drug approved for marketing by FDA
Ayana Pharma Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 31 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Ayana Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, external profiles, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 514782622 |
| Crunchbase | ayana-pharma |
| Phone | +97225722041 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-15T00:00:00.000Z |
| Created | 2016-01-26T00:00:00.000Z |